Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 7, 2014; 20(13): 3525-3533
Published online Apr 7, 2014. doi: 10.3748/wjg.v20.i13.3525
Published online Apr 7, 2014. doi: 10.3748/wjg.v20.i13.3525
Table 1 Interaction between inflammatory bowel disease therapy and anti-reject therapy in inflammatory bowel disease patients after liver transplantation
Drug | Efficacy | Ref. | |
IBD therapy | Anti-reject therapy | ||
5-ASA | + | [3] | |
[12] | |||
Prednisone | + | + | [12] |
[21] | |||
Azathioprine | + | + | [2] |
Anti-TNFα | + | [15] | |
[16] | |||
[13] | |||
[14] | |||
[18] | |||
Tacrolimus | - | + | [2] |
[3] | |||
Cyclosporine | + | + | [3] |
Mycophenolate | - | + | [22] |
Mofetil | [23] |
- Citation: Indriolo A, Ravelli P. Clinical management of inflammatory bowel disease in the organ recipient. World J Gastroenterol 2014; 20(13): 3525-3533
- URL: https://www.wjgnet.com/1007-9327/full/v20/i13/3525.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i13.3525